Versartis Inc (VSAR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Versartis Inc (VSAR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7607
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Versartis Inc (Versartis) is a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of endocrine disorders. The company’s lead product candidate include somavaratan (VRS-317) is a recombinant human growth hormone (GHD) that is designed to reduce the burden of daily injection therapy which is used in the treatment of growth hormone deficiency in both children and adults. It utilizes half-life extension technology, a proprietary recombinant polypeptide technology for development of its products. The company serves life science industry. Versartis is headquartered in Menlo Park, California, the US.

Versartis Inc (VSAR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Versartis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Versartis Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Versartis Raises US$55 Million In Series E Financing 10
Versartis Secures USD12.49 Million in Series C Venture Funding 12
Versartis Raises US$20 Million In Series D Financing 13
Versartis Raises US$25 Million In Series C Financing 15
Licensing Agreements 17
Teijin Pharma Enters into Licensing Agreement with Versartis 17
Equity Offering 19
Versartis Raises USD63.4 Million in Public Offering of Shares 19
Versartis Raises USD86.3 Million in Public Offering of Shares 21
Versartis Completes IPO Of For US$145 Million 23
Versartis Inc – Key Competitors 25
Versartis Inc – Key Employees 26
Versartis Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 07, 2018: Versartis announces second quarter 2018 financial results 28
May 08, 2018: Versartis Reports First Quarter 2018 Financial Results 30
Mar 01, 2018: Versartis Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 31
Oct 26, 2017: Versartis Reports Third Quarter 2017 Financial Results and Provides Corporate Update 33
Jul 27, 2017: Versartis Reports Second Quarter 2017 Financial Results 34
Apr 27, 2017: Versartis Reports First Quarter 2017 Financial Results 36
Feb 21, 2017: Versartis Reports Fourth Quarter 2016 Financial Results 37
Corporate Communications 39
Sep 05, 2017: Versartis Announces Expansion of Executive Leadership Team with Addition of Dr. Robert Gut as the Head of Global Clinical, Medical and Regulatory Affairs 39
Jun 01, 2017: Versartis Appoints Eric Dobmeier to Board of Directors 40
Apr 25, 2017: Versartis Appoints Jay Stout, Ph.D., as Senior Vice President, Technical Operations 41
Mar 15, 2017: Versartis Appoints Tracy Woody as Chief Commercial Officer 42
Jan 31, 2017: Versartis announces management changes 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Versartis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Versartis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Versartis Raises US$55 Million In Series E Financing 10
Versartis Secures USD12.49 Million in Series C Venture Funding 12
Versartis Raises US$20 Million In Series D Financing 13
Versartis Raises US$25 Million In Series C Financing 15
Teijin Pharma Enters into Licensing Agreement with Versartis 17
Versartis Raises USD63.4 Million in Public Offering of Shares 19
Versartis Raises USD86.3 Million in Public Offering of Shares 21
Versartis Completes IPO Of For US$145 Million 23
Versartis Inc, Key Competitors 25
Versartis Inc, Key Employees 26
Versartis Inc, Subsidiaries 27

List of Figures
Versartis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Versartis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Versartis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Versartis Inc (VSAR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Austin Exploration Limited (AKK)-石油・ガス分野:企業M&A・提携分析
    Summary Austin Exploration Limited (Austin) is upstream oil and gas company that acquires, explores, develops, and produces oil and natural gas in the US. The company holds working interests in Colorado in the DJ Basin with the Niobrara and Pierre Shale as its primary oil and gas formations. It also …
  • Electra Private Equity PLC (ELTA):企業の財務・戦略的SWOT分析
    Electra Private Equity PLC (ELTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Omnicom Group, Inc.:企業の戦略・SWOT・財務情報
    Omnicom Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Omnicom Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Abbott Molecular Inc:医療機器:M&Aディール及び事業提携情報
    Summary Abbott Molecular Inc (Abbott Molecular), formerly Vysis Inc, a subsidiary of Abbott Laboratories, is a medical diagnostics company that provides molecular testing solutions. The company offers infectious disease products, oncology products, genetics products, automation products, molecular d …
  • Strabag SE:企業の戦略・SWOT・財務情報
    Strabag SE - Strategy, SWOT and Corporate Finance Report Summary Strabag SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Sorgenia SpA:企業の戦略的SWOT分析
    Sorgenia SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Sumitomo Bakelite Co Ltd (4203):企業の戦略的SWOT分析
    Sumitomo Bakelite Co Ltd (4203) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Eastman Kodak Company (KODK):企業の財務・戦略的SWOT分析
    Eastman Kodak Company (KODK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Range Resources Corp (RRC)-石油・ガス分野:企業M&A・提携分析
    Summary Range Resources Corp (Range) is independent oil, natural gas and natural gas liquids (NGL) company that explores, develops, and acquires natural gas and oil properties in the US. It has oil and gas properties in the Appalachian basin and Northern Louisiana of the US. Range’s natural gas and …
  • Ornua Co-operative Limited:企業の戦略・SWOT・財務情報
    Ornua Co-operative Limited - Strategy, SWOT and Corporate Finance Report Summary Ornua Co-operative Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • TranSystems Corporation:企業の戦略・SWOT・財務情報
    TranSystems Corporation - Strategy, SWOT and Corporate Finance Report Summary TranSystems Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • HSS Engineers Berhad (HSSEB):企業の財務・戦略的SWOT分析
    HSS Engineers Berhad (HSSEB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Almac Discovery Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Almac Discovery Ltd (Almac Discovery), a subsidiary of Almac Group Ltd is a healthcare service provider that discovers and develops drugs for the treatment of cancer. The company develops drugs, small molecule and therapeutic peptide, biomarkers and diagnostic tools. It provides early drug d …
  • Symbolic Displays, Inc.:企業の戦略・SWOT・財務情報
    Symbolic Displays, Inc. - Strategy, SWOT and Corporate Finance Report Summary Symbolic Displays, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • MDU Resources Group, Inc.:企業の戦略・SWOT・財務情報
    MDU Resources Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary MDU Resources Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Drax Group Plc:企業の発電所・SWOT分析2018
    Drax Group Plc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exe …
  • Turner Broadcasting System Inc:企業の戦略的SWOT分析
    Turner Broadcasting System Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Interseguro Compania de Seguros SA:企業の戦略・SWOT・財務分析
    Interseguro Compania de Seguros SA - Strategy, SWOT and Corporate Finance Report Summary Interseguro Compania de Seguros SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • The Bangchak Petroleum PCL (BCP):石油・ガス:M&Aディール及び事業提携情報
    Summary The Bangchak Petroleum PCL (Bangchak) is an oil and gas company. It carries out import of crude oil from both indigenous and overseas sources, and refines it into finished petroleum products. Its refinery produces gasoline, gasohol and diesel products. The company markets its petroleum produ …
  • National Gas & Industrial Co (2080):企業の財務・戦略的SWOT分析
    National Gas & Industrial Co (2080) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆